Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Abroad (travel likely)RecruitingPHASE2
Conditions
Sickle Cell Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Children's National Health System, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Maryanne Odinakachukwu) · modinakach@childrensnational.org · 202-476-2957Contact: Principal Investigator (Robert Nickel, MD)Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Sonali Chaudhury, MD)Columbia University, New York, New York, United States
Contact: Principal Investigator (Monica Bhatia)Levine Children's Hospital, Charlotte, North Carolina, United States
Contact: Principal Investigator (Michael Kent, MD)Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Hemalatha Rangarajan) · Hemalatha.Rangarajan@nationwidechildrens.org · 614-355-1689Contact: Principal Investigator (Hemalatha Rangarajan, MD)Alberta Children's Hospital, Calgary, Alberta, Canada
Contact: Study coordinator (Gregory Guilcher)Contact: Principal Investigator (Gregory Guilcher, MD)The Hospital for Sick Children, Toronto, Ontario, Canada
Contact: Principal Investigator (Muhammad Ali, MD)
Study leads
Robert Nickel, MD
Principal Investigator
Children's National Research Institute